IMTX logo

IMTX Immatics N.V.

NASDAQ Capital Market · Biotechnology · Healthcare

$5.77
-0.18 (-3.03%)

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTe…

Market Cap: $863.40Mwww.immatics.com

Price

No data yet.

Social Signal Score

44
5d
—
30d
45
4 mentions
—
60d
45
4 mentions
—
90d
43
6 mentions
—
news: 6

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 0Sell 0Strong Sell 0
Avg price target$17.67+206.2%
Low $15Median $17High $21
Current Consensus

Revenue

$6.92M+634.54%
$942.5K$34.93M$68.92M$102.91M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-1.95
$-2.22–$-1.69
6 analysts
FY2026
$-2.10
$-2.20–$-2.00
6 analysts
FY2027
$-2.12
$-2.60–$-1.82
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Harpreet Singh
Sector
Healthcare
Industry
Biotechnology
Employees
704
Beta
1.35
Country
DE
Piotroski score
1 / 9 (Weak)
Altman Z-score
0.87
www.immatics.com